Podcasts about Acute myeloid leukemia

In this episode of the Oncology Brothers podcast, we discussed two challenging cases focused on Acute Myeloid Leukemia (AML). We welcomed Dr. Naval Daver, a leading expert from MD Anderson Cancer Center, to discuss: therapy-related AML and de novo AML where induction chemotherapy is not an option. Episode Highlights: • Overview of therapy-related AML and its increasing prevalence due to advancements in solid tumor treatments. • In-depth discussion on the prognosis and treatment options for patients with complex cytogenetics. • Comparison of induction treatments: CPX-351 vs. the traditional 7 + 3 regimen, including survival rates and side effects. • Insights into the use of hypomethylating agents combined with venetoclax for older patients with AML, particularly those with NPM1 mutations. • Practical considerations for administering these treatments in both inpatient and outpatient settings. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of AML management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on treatment algorithms, conference highlights, and the latest FDA approvals! #AcuteMyeloidLeukemia, #TherapyRelatedAML, #DeNovoAML, #TransplantIneligible, #OncologyBrothers

Persistent colds and a chronic cough were followed by not being able to walk and being constantly tired for Marie Gulliver's 2 year old son Ezra in 2022. These symptoms were finally diagnosed as High Risk Acute Myeloid Leukemia, which was complicated by a genetic mutation and the always difficult Graft vs, Host Disease after Ezra received a successful Bone Marrow Transplant in September of 2022. Ezra has been cancer free for more than 3 years and has ony a 5 percent chance of a relapse which is great news for him and his family.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GFF865. CME/EBAH/AAPA/IPCE credit will be available until January 4, 2027.Menin Masters for AML Care: Guidance on Integrating Menin Inhibitor Regimens & Boosting Efficacy in Challenging AML Subtypes In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic movements shaping the future of healthcare.The pharmaceutical and biotech sectors are undergoing significant transformations, driven by scientific breakthroughs, regulatory developments, and strategic shifts. At the forefront is Eli Lilly's impressive lineup of investigational cardiometabolic drugs, spotlighted in Clarivate's "Drugs to Watch in 2026" report. This signals a robust focus on combating cardiometabolic disorders, which have vast implications for global health due to their widespread prevalence. The report also highlights Johnson & Johnson's competitive position in this therapeutic area, indicating a dynamic landscape where innovation is key.In oncology, Jazz Pharmaceuticals is making waves with its bispecific antibody, Ziihera, positioning it as a preferred HER2-targeted therapy for stomach cancer. This development marks a shift towards precision medicine and targeted therapies, which are gradually supplanting traditional treatments like Herceptin. The promising efficacy of Ziihera could revolutionize treatment protocols for HER2-positive gastric cancer patients, enhancing survival outcomes and quality of life.Meanwhile, a legal confrontation has erupted between Bayer and leading COVID-19 vaccine developers such as Moderna, Johnson & Johnson, and Pfizer-BioNTech. Bayer alleges patent infringement on intellectual property developed years prior. This lawsuit underscores the intricate relationship between innovation and intellectual property rights in the pharmaceutical industry, especially poignant in the aftermath of the COVID-19 pandemic.Daiichi Sankyo's collaboration with Genesis to commercialize Vanflyta—an acute myeloid leukemia treatment—across 13 European countries highlights strategic movements in oncology. Approved in 2023, this partnership exemplifies Daiichi's commitment to expanding its European market presence and improving patient access to critical cancer therapies.GSK's promising Phase 3 results for its hepatitis B drug candidate represent a potential breakthrough as a "functional cure." Such advancements could redefine management strategies for hepatitis B, a chronic infection affecting millions worldwide. The positive trial outcomes pave the way for FDA submission, showcasing GSK's dedication to addressing unmet medical needs through innovative approaches.Amgen's strategic partnership with Disco Pharmaceuticals illustrates ongoing investment in oncology research. With a $618 million agreement focused on cancer target discovery, Amgen leverages Disco's expertise to fortify its oncology pipeline. This collaboration underscores the significance of cooperative innovation in drug development and enhancing therapeutic options.In gene therapy, Ikarovec and VectorBuilder are advancing eye disease treatments through an innovative partnership. Their $1 billion deal aims to make gene therapies more accessible by enabling administration outside specialized settings—a transformative approach that could democratize advanced treatments.Hope Biosciences' Phase 2 study results offer hope for Parkinson's disease patients through stem cell therapy improvements in motor function. Despite some data discrepancies, these findings set the stage for Phase 3 trials and underscore the potential of stem cell therapies in neurological disorders.The pharmaceutical industry also grapples with economic challenges as layoffs rise by 16% year-over-year in 2025. Concurrently, despite regulatory hurdles and macroeconomic uncertainties, the FDA approved 55 new treatments and vaccines—a testament to resilience and innovation within biopharma.In regulatory dynamics, GSK's Exdensur received approval in Japan for treating severe asthma and chronic rhinosinusitisSupport the show

Featuring perspectives from Dr Harry Paul Erba, Dr Amir Fathi, Dr Tara L Lin, Dr Alexander Perl and Dr Eytan M Stein, including the following topics:  Introduction (0:00) Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin (1:46) Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl (25:38) Role of FLT3 Inhibitors in AML Management — Dr Erba (48:27) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi (1:10:28) Current and Future Role of Menin Inhibitors in the Treatment of AML — Dr Stein (1:37:29) CME information and select publications

Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania's Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here.

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Motivate to Move, we continue our powerful conversation with Boyd Dunleavey, a two-time Acute Myeloid Leukemia survivor who has faced more in life than most could imagine. In Part 2, Boyd dives into what keeps him grounded: healthy eating, positive lifestyle choices, and the power of intermittent fasting. He shares which fasting approach works best for him and how moderation and self-control have become the foundation for his health and happiness — and the perfect title for this episode. Boyd also opens up about living with neuropathy, his two Halifax Marathons (both incredibly tough races), and the sheer determination it took to complete them. Since a serious car accident, he's run eight of his eighteen marathons, proving once again that his drive and faith know no limits. Of course, there's a little fun mixed in too — from Disney runs and unforgettable post-race cookies (yes, the chocolate chip and shortbread kind!) to his hopeful plans for another Fredericton full or half marathon this spring, if his health allows. This conversation captures everything Motivate to Move is about: perseverance, gratitude, balance, and the joy of just keeping on moving.Motivate to Move email:motivatetomove.podcast#gmail.comMotivate to Move YouTube channel:https://www.facebook.com/search/top?q=motivate%20to%20movePlease donate blood today and give the gift of life.Become a supporter of this podcast: https://www.spreaker.com/podcast/motivate-to-move--4528736/support.

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).  We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML. Key topics covered in this episode included: The mechanism of action of Ziftomenib as a menin inhibitor Study findings from KOMET-001 and patient response rates Management of side effects, including differentiation syndrome and QTc prolongation Comparison with other menin inhibitors like Revumenib Future directions for combination therapies and sequencing of treatments Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights. #Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several groundbreaking advancements and strategic shifts in the industry that promise to reshape the landscape of patient care and therapeutic innovations.The U.S. Food and Drug Administration has introduced a novel regulatory pathway aimed at expediting the approval process for custom gene-editing therapies. Articulated by FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., this new approach is set to revolutionize personalized medicine, particularly for genetic disorders where tailored interventions are crucial. Gene editing technologies, like CRISPR-Cas9, have opened unprecedented avenues for addressing genetic conditions directly at their source. However, the regulatory framework has struggled to keep pace with these advances, often hampering innovation with lengthy and complex approval processes.This proposed pathway seeks to streamline these requirements by adopting a risk-based assessment model that considers the unique properties of gene-editing therapies. Unlike traditional drugs, which follow a uniform clinical trial path, gene-editing treatments require a more nuanced regulatory approach due to their precision and potential off-target effects. The framework emphasizes adaptive trial designs—allowing for modifications based on interim results—and integrates real-world data to create a dynamic regulatory process. This not only promises faster development times but also fosters innovation by making it easier for companies to bring cutting-edge therapies to market.The implications are far-reaching. For researchers and biotech firms, this represents a chance to reduce time-to-market significantly while maintaining high safety standards. It also sets a precedent for future regulatory models that prioritize patient-centric approaches, acknowledging the diverse genetic landscapes of individuals with rare diseases. On a broader scale, this shift underscores the increasing recognition of personalized medicine's potential to transform healthcare delivery.In parallel developments, Gilead Sciences has achieved positive phase 3 results for its single-tablet regimen combining bictegravir and lenacapavir for HIV treatment. This milestone offers hope for simplifying treatment protocols for patients currently on multi-tablet regimens, potentially enhancing adherence and improving health outcomes. Gilead's preparation for regulatory filings marks an essential step forward in their therapeutic portfolio.Turning to cancer treatment advancements, Kyowa Kirin's collaboration with Kura Oncology has led to FDA approval for an oral medication targeting a subset of acute myeloid leukemia patients. This approval highlights the power of strategic partnerships in expediting the development of targeted cancer therapies and brings new hope to patients with limited treatment options.Meanwhile, several pharmaceutical companies, including Fresenius, Sun Pharma, and Teva, have been involved in product recalls ranging from hospital drugs to antibiotics and ADHD medications. These recalls underscore ongoing challenges in maintaining drug safety standards and emphasize the need for rigorous quality control measures across the industry.Zealand Pharma has opted to pause development of its dual GLP-1/GLP-2 agonist, dapiglutide, due to an increasingly crowded metabolic disorder treatment landscape. By reallocating resources towards programs with greater clinical differentiation potential, Zealand reflects broader industry trends prioritizing investments in areas with clearer paths to market success.In malaria treatment advances, Novartis has achieved significant progress with its next-generation drug 'Ganlum,Support the show

Featuring an interview with Dr Eunice S Wang, including the following topics: Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00) All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39) Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07) Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14) Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24) Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54) Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30) CME information and select publications

Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics: All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00) Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21) First- and second-generation IDH inhibitors for AML (17:40) Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59) Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42) Novel combination approaches with menin inhibitors for AML (29:11) CME information and select publications

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

Featuring an interview with Dr Ghayas Issa, including the following topics: Mechanism of action and efficacy of menin inhibitors (0:00) Presentation and management of differentiation syndrome (13:31) Role of menin inhibitors in other cancers (18:19) Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51) Mechanisms of resistance to menin inhibition in AML (26:53) Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31) Mechanism of action of menin inhibitors as differentiation agents (38:05) Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55) Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25) Other investigational therapeutic strategies in AML (54:39) CME information and select publications

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics: Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00) Side effects of menin inhibition (10:54) Mechanisms of resistance to menin inhibition in AML (15:08) CME information and select publications

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Losing one child is terrible under any circumstances but losing 2 children, to different tragedies is more than anyone should ever be burdened with. Adrienne Bender will talk about the loss of her 15 year old daughter Mackenzie who was diagnosed with Acute Myeloid Leukemia after being diagnosed with this Pediatric Blood cancer when she was 8 years old in 2011, was in remission for 5 years, then relapsed and passed away in 2018. Adrienne will also talk about her son Kyler, who developed substance abuse problems beginning when he was 12 years old, fought his demons, and was on his way to what was thought to be a complete recovery before he got into a fight, took fentanyl, and passed away in 2023

An elite swim coach known for training Olympic hopefuls suddenly finds themself on the other side of perseverance. Diagnosed with acute myeloid leukemia (AML), they face their toughest challenge yet- a fight for their life. After grueling rounds of chemotherapy and a bone marrow transplant, The University of Kansas Cancer Center helped them emerge with a renewed purpose and perspective.

Gaby Laurent's story starts the way every story should start; with an awesome, loving and supportive family and a wonderful upbringing. She grew up with love and the push, the drive and the support to have a great life. And when she went off to college she met the love of her life on the first day. Graduation, graduate school, marriage, career, and then pregnancy… everything that she wanted. Then came the diagnosis that changed her life. AML. Acute Myeloid Leukemia. While pregnant. No one had ever gone through the aggressive AML treatment while pregnant. Ever. Gaby was a medical unicorn as is her son Louis who went through chemotherapy while in utero. The story is harrowing but Gaby, along with family, went through it with incredible grace, humor, and a level of positivity that I struggle to comprehend. She tells the story in her book Wrinkles Welcome with the same level of humor and passion that is both profoundly powerful and amazing to watch, listen or read. Today, Gaby is healthy, happy, married with two boys and has a very active life full of gratitude, community and adventure. She believes in the power of community, faith and nature to help heal those in this very difficult place and she uses her experience to support and influence other cancer fighters and survivors, through her book, and as a camp director.

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

Featuring an interview with Dr Jorge Cortes, including the following topics: Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00) Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38) Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32) Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04) Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31) Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07) Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53) CME information and select publications

Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics: Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00) CME information and select publications

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML. Key topics included: •⁠  ⁠The importance of retesting for FLT3 mutations at the time of relapse •⁠  ⁠Treatment paradigms for fit vs. unfit patients •⁠  ⁠The role of Gilteritinib and combination therapies in relapsed settings •⁠  ⁠Management of side effects, including cytopenias and differentiation syndrome •⁠  ⁠Insights into the use of hypomethylating agents and the potential of oral therapies Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on the latest in oncology!

In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice. Episode Highlights: • Understanding the current standard of care for AML, including diagnosis and risk stratification. • The importance of molecular profiling and how it influences treatment decisions. • A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML. • Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy. • The role of targeted therapies in both upfront treatment and relapsed/refractory settings. • Key considerations for managing side effects, including cytopenias and infections. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ YouTube: https://youtu.be/gbgRbrjHxmQ Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.  Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.Presenters:Eytan M. Stein, MDChief, Leukemia ServiceDirector, Program for Drug Development in LeukemiaAssociate Attending PhysicianLeukemia Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkEunice S. Wang, MDChief, Leukemia ServiceProfessor of OncologyDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkLink to full program: https://bit.ly/4f4an0O

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

In this incredible episode of Marrow Masters, we sit down with Kayla West, a stem cell donor from Texas, and Miriam Bauer, the mother of a young leukemia survivor Miley, from Oklahoma. This story is a deeply emotional journey of hope, resilience, and a connection that transcends bloodlines. Kayla and Miriam take us through the entire transplant process from both perspectives: the donor stepping up during a pandemic, and the caregiver navigating a life-threatening diagnosis in a child.We begin with Kayla's decision to join the donor registry after a chance encounter with DKMS at a Goo Goo Dolls concert. She didn't expect to be called to donate, but when she was, during COVID lockdown, she jumped at the chance to help someone—anyone—in need. That “anyone” turned out to be Miley, an eleven-year-old girl who had been diagnosed with acute myeloid leukemia (AML) and urgently needed a transplant after two brutal rounds of chemotherapy.Miriam recounts those terrifying early days at St. Jude, from the moment of diagnosis through the chaos of the early pandemic lockdowns. She was Miley's only caregiver during a 248-day hospital stay. Her story is filled with moments of heartbreak and triumph, from failed chemo rounds to the joy of reaching remission and finding a viable donor in Kayla. We learn how transplant coordination works, how donor cells were frozen and shipped during COVID, and how little details—like celebrating donor day or choosing a transplant date that coincides with family birthdays—brought joy in dark times.Post-transplant, Miley's life has been a mix of recovery and lingering health effects, but she's thriving. Miriam emphasizes advocacy, honesty, and self-care for caregivers. Kayla, for her part, reflects on the overwhelming emotion of learning she was a match, undergoing all the testing during COVID, and then finally meeting the recipient of her cells in an unforgettable reunion in New York. The two families, now bonded for life, meet regularly and have built a deep friendship.  Next up: A trip for Kayla's family to Oklahoma to experience a powwow with Miriam, Miley, and their family!The videos below will have you reaching for the tissues and hopefully inspire many to get swabbed.Kayla also shares her decision to launch a nonprofit, SETX Leukemia Organization, focused on educating communities and recruiting new donors. Her goal is to prevent other families from facing what Miriam's did—wondering if there will be a match in time. Kayla's drive, born from her experience, continues to ripple outwards as she recruits more potential donors at local events with DKMS support.This episode isn't just about survival—it's about connection, purpose, and what can happen when strangers become family through an act of extraordinary generosity.SETX Leukemia Organization (Kayla's nonprofit): https://setxleukemia.org/DKMS (Be The Match partner organization): https://www.dkms.orgDKMS Video about Kayla, Miley, and Miriam: https://www.youtube.com/watch?v=sNhwRxXMbw8Thanks to our Season 17 Sponsors:Leukemia and Lymphoma Society (LLS): https://lls.org/and Incyte: https://incyte.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd

Jennifer Vertentes was a police officer in Providence Rhode Island when she decided to go to Hasbro Children's Hospital on Thanksgiving Day of 2018 to meet kids who had to spend their Thanksgiving being treated for different reasons, including being treated for Pediatric Cancer. While she was there she met 3 year old Emerson Lucier who was going through her 3rd battle with Acute Myeloid Leukemia . This meeting inspired Jennifer to start her HERO PACKAGE FOUNDATION to help put a smile on the faces of these kids who were battling these difficult diseases. Jennifer, who in 2023 had to retire from the Police Department after suffering an injury while trying to save a person who was drowning, was also diagnosed with Ovarian Cancer that year. Fortunately for the Pediatric Cancer community, she continues to help these kids as she deals with her disease, that fortunately was diagnosed at a very early stage. 

Kelsey Lauria began to have massive headaches early in the fall of her senior year in high school in 2014 which led to her diagnosis of Acute Myeloid Leukemia. In the later part of the winter in 2015, Kelsey experienced heart failure which led to her passing on April 18th, just 6 days after her 18th birthday and less than 6 months after her cancer diagnosis. During her treatment, Kelsey started her Bald Beauties Project to help in the fight against Pediatric Cancer and this successful non-profit has been run by her mom Maya since Kelsey's passing. 

Imagine the shock and horror of having a child be diagnosed with Acute Myeloid Leukemia, going through treatment for that for 8 months,, relapsing 2 months later, and then being told that the first diagnosis was wrong, and that the child actually had  Ewings Sarcoma. That is what happened to then 2 1/2 year old Connor Mocey who is now 5 years old and doing as well as possible while dealing with this difficult Bone Cancer. 

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation